BB has dampened the hype that FDA approval created with the worst CR of 2016. It didn't finalise until 2017 and still more options dilution until 2018.
Ever since limited sales & marketing activity and LBT has fallen into its shell.
We need a proactive CEO that can sell APAS to the world and bring in distribution agreements in quick time before competitors take our market share.
LBT Price at posting:
28.0¢ Sentiment: Buy Disclosure: Held
